Repligen/$RGEN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Repligen
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration and fluid management is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
- Ticker
- $RGEN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 2,000
- Headquarters
- Waltham, United States
- Website
- www.repligen.com
Repligen Metrics
BasicAdvanced
$11B
-
-$0.21
1.08
-
Price and volume
Market cap
$11B
Beta
1.08
52-week high
$198.87
52-week low
$100.99
Average daily volume
1.3M
Financial strength
Current ratio
9.882
Quick ratio
8.069
Long term debt to equity
0.321
Total debt to equity
0.331
Interest coverage (TTM)
2.72%
Profitability
EBITDA (TTM)
143.498
Gross margin (TTM)
53.77%
Net profit margin (TTM)
-1.47%
Operating margin (TTM)
8.14%
Effective tax rate (TTM)
243.43%
Revenue per employee (TTM)
$400,000
Management effectiveness
Return on assets (TTM)
1.40%
Return on equity (TTM)
-0.57%
Valuation
Price to revenue (TTM)
13.209
Price to book
5.11
Price to tangible book (TTM)
15.59
Price to free cash flow (TTM)
101.101
Free cash flow yield (TTM)
0.99%
Free cash flow per share (TTM)
1.866
Growth
Revenue change (TTM)
13.80%
Earnings per share change (TTM)
-922.87%
3-year revenue growth (CAGR)
7.28%
10-year revenue growth (CAGR)
23.15%
3-year earnings per share growth (CAGR)
-50.88%
10-year earnings per share growth (CAGR)
0.09%
What the Analysts think about Repligen
Analyst ratings (Buy, Hold, Sell) for Repligen stock.
Analyst projections of the future price of Repligen stock.
Bulls say / Bears say
Q3 revenue rose 12.5% organically, and Repligen raised its 2026 revenue guidance to $844–$852 million. Adjusted operating margin also expanded year on year. (Repligen Corporation)
The completed BioLife acquisition adds recurring consumables used in cell therapy, including products supporting 18 commercially approved therapies. Repligen expects the deal to add at least $0.05 to adjusted earnings per share in its first year. (Repligen Corporation, Repligen Corporation)
Capital equipment orders grew at a mid-teens rate and reached their highest quarterly level in five years, leaving Repligen with a stronger backlog entering 2027. (The Motley Fool)
Filtration revenue fell 11% in Q3, reflecting disclosed customer headwinds and the PolyMem divestiture. Some system deliveries were also pushed into 2027. (The Motley Fool)
Capital equipment sales have not yet caught up with order momentum: Q3 orders rose, but recognised revenue declined as customers requested later deliveries. That makes the timing of backlog conversion a risk to near-term growth. (The Motley Fool)
Demand recovery remains uneven: emerging-biotech revenue grew only at a mid-single-digit rate in Q3, compared with high-teens growth year to date. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 30 Oct 2026.
Repligen Financial Performance
Revenues and expenses
Repligen Earnings Performance
Company profitability
Upcoming events
No upcoming events
Repligen News
AllArticlesVideos
Funds containing Repligen
AllUSDEURGBP
Fund name | Fund size | $RGEN weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.95% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.95% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.95% |
SPDR S&P 400 US Mid Cap$SPY4 | $6.4B | 0.34% |
SPDR S&P 400 US Mid Cap£SPX4 | $6.4B | 0.34% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.